Kyoto global consensus report on Helicobacter pylori gastritis
- PMID: 26187502
- PMCID: PMC4552923
- DOI: 10.1136/gutjnl-2015-309252
Kyoto global consensus report on Helicobacter pylori gastritis
Abstract
Objective: To present results of the Kyoto Global Consensus Meeting, which was convened to develop global consensus on (1) classification of chronic gastritis and duodenitis, (2) clinical distinction of dyspepsia caused by Helicobacter pylori from functional dyspepsia, (3) appropriate diagnostic assessment of gastritis and (4) when, whom and how to treat H. pylori gastritis.
Design: Twenty-three clinical questions addressing the above-mentioned four domains were drafted for which expert panels were asked to formulate relevant statements. A Delphi method using an anonymous electronic system was adopted to develop the consensus, the level of which was predefined as ≥80%. Final modifications of clinical questions and consensus were achieved at the face-to-face meeting in Kyoto.
Results: All 24 statements for 22 clinical questions after extensive modifications and omission of one clinical question were achieved with a consensus level of >80%. To better organise classification of gastritis and duodenitis based on aetiology, a new classification of gastritis and duodenitis is recommended for the 11th international classification. A new category of H. pylori-associated dyspepsia together with a diagnostic algorithm was proposed. The adoption of grading systems for gastric cancer risk stratification, and modern image-enhancing endoscopy for the diagnosis of gastritis, were recommended. Treatment to eradicate H. pylori infection before preneoplastic changes develop, if feasible, was recommended to minimise the risk of more serious complications of the infection.
Conclusions: A global consensus for gastritis was developed for the first time, which will be the basis for an international classification system and for further research on the subject.
Keywords: FUNCTIONAL DYSPEPSIA; GASTRIC CANCER; GASTRITIS; HELICOBACTER PYLORI - GASTRITIS; HELICOBACTER PYLORI - TREATMENT.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4552923/bin/gutjnl-2015-309252f01.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4552923/bin/gutjnl-2015-309252f02.gif)
Comment in
-
Helicobacter pylori: Helicobacter pylori gastritis--a novel distinct disease entity.Nat Rev Gastroenterol Hepatol. 2015 Oct;12(10):556-7. doi: 10.1038/nrgastro.2015.158. Epub 2015 Sep 15. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26369312
Similar articles
-
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368. Epub 2020 Oct 1. Gut. 2020. PMID: 33004546
-
Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis.World J Gastroenterol. 2020 Feb 7;26(5):466-477. doi: 10.3748/wjg.v26.i5.466. World J Gastroenterol. 2020. PMID: 32089624 Free PMC article. Review.
-
Kyoto global consensus report on Helicobacter pylori gastritis and its impact on Chinese clinical practice.J Dig Dis. 2016 Jun;17(6):353-6. doi: 10.1111/1751-2980.12358. J Dig Dis. 2016. PMID: 27164026
-
[Kyoto global consensus report for treatment of Helicobacter pylori and its implications for China].Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 Jan;45(1):1-4. doi: 10.3785/j.issn.1008-9292.2016.01.01. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016. PMID: 27045234 Free PMC article. Chinese.
-
Helicobacter pylori: Helicobacter pylori gastritis--a novel distinct disease entity.Nat Rev Gastroenterol Hepatol. 2015 Oct;12(10):556-7. doi: 10.1038/nrgastro.2015.158. Epub 2015 Sep 15. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26369312
Cited by
-
Comprehensive insights on treatment modalities with conventional and herbal drugs for the treatment of duodenal ulcers.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun 5. doi: 10.1007/s00210-024-03178-5. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38837070 Review.
-
Addressing Challenges in Standardizing Helicobacter pylori Treatment Protocols: Importance and Review.Cureus. 2024 Apr 30;16(4):e59394. doi: 10.7759/cureus.59394. eCollection 2024 Apr. Cureus. 2024. PMID: 38817468 Free PMC article. Review.
-
Minocycline in the eradication of Helicobacter pylori infection: A systematic review and meta-analysis.World J Gastroenterol. 2024 May 7;30(17):2354-2368. doi: 10.3748/wjg.v30.i17.2354. World J Gastroenterol. 2024. PMID: 38813048 Free PMC article.
-
Helicobacter pylori Treatment and Gastric Cancer Risk Among Individuals With High Genetic Risk for Gastric Cancer.JAMA Netw Open. 2024 May 1;7(5):e2413708. doi: 10.1001/jamanetworkopen.2024.13708. JAMA Netw Open. 2024. PMID: 38809553 Free PMC article.
-
Yiwei Xiaoyu granules for treatment of chronic atrophic gastritis with deficiency syndrome of the spleen and stomach.World J Clin Cases. 2024 May 6;12(13):2201-2209. doi: 10.12998/wjcc.v12.i13.2201. World J Clin Cases. 2024. PMID: 38808353 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical